Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SOPHiA GENETICS ( (SOPH) ) has issued an update.
On January 12, 2026, SOPHiA GENETICS reported strong preliminary, unaudited results for 2025, with full-year revenue of about $77 million, up roughly 18% year-on-year, and more than 391,000 analyses performed on its SOPHiA DDM™ platform, including over 105,000 analyses and at least $21 million in revenue in the fourth quarter alone. The company signaled continued momentum by issuing 2026 revenue guidance of $92–94 million, implying 20–22% growth, alongside an expected adjusted EBITDA loss of $29–32 million, and outlined a significant leadership transition: President Ross Muken, a key architect of its commercial transformation since joining as CFO in 2021, will become CEO on July 1, 2026, while co-founder and current CEO Jurgi Camblong will move to the role of Executive Chairman, with long-time executive Kevin Puylaert stepping up as Chief Sales Officer in January 2026, underscoring a planned succession aimed at sustaining growth and strengthening the company’s position in AI-powered precision medicine.
The most recent analyst rating on (SOPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.
Spark’s Take on SOPH Stock
According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.
SOPHiA GENETICS’ overall stock score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. While technical analysis shows positive momentum, valuation concerns due to ongoing losses weigh heavily. The earnings call highlights strong growth and strategic initiatives, but these are not enough to offset the financial challenges.
To see Spark’s full report on SOPH stock, click here.
More about SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company specializing in AI-driven precision medicine for cancer and rare diseases. Its flagship SOPHiA DDM™ platform analyzes complex genomic and multimodal data to deliver real-time, actionable insights to a global network of hospitals, laboratories and biopharma partners across more than 70 countries.
Average Trading Volume: 100,296
Technical Sentiment Signal: Buy
Current Market Cap: $336.5M
Find detailed analytics on SOPH stock on TipRanks’ Stock Analysis page.